

# Financial Tear Sheet

## Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

## Primary IR Contact

### Solebury Trout

Annie Chang

Phone: 646-378-2972

E-mail:

[achang@troutgroup.com](mailto:achang@troutgroup.com)

## Stock Performance

### IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$9.42**

Change (%) **▲ 0.06 (0.64%)**

Volume 744,817

52 Week High \$19.90

52 Week Low \$7.26

Market Cap \$1,160,256,954

Rolling EPS -1.36

PE Ratio 0

Shares Outstanding 123,169,528

Data as of January 18, 2019 4:00 p.m. ET



## Recent Headlines

December 21, 2018

[Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference](#)

November 13, 2018

[Iovance Biotherapeutics to Participate at November Investor Conferences](#)

November 6, 2018

[Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
January 7, 2019	<a href="#">8-K</a>
December 20, 2018	<a href="#">4</a>
December 14, 2018	<a href="#">4</a>
December 7, 2018	<a href="#">SC 13D/A</a>

## Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.

---

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.